Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $10.34 and traded as low as $10.06. KalVista Pharmaceuticals shares last traded at $10.33, with a volume of 1,065,416 shares traded. A number of analysts […]
KalVista Pharmaceuticals (NASDAQ:KALV – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant […]
KalVista Pharmaceuticals (NASDAQ:KALV – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors […]
Equities analysts expect KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) to report earnings per share of ($1.01) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for KalVista Pharmaceuticals’ earnings, with estimates ranging from ($1.19) to ($0.81). KalVista Pharmaceuticals posted earnings per share of ($0.65) during the same quarter last […]